The biggest predictors of survival following hematopoietic transplantation (HCT) for patients with hematologic malignancy are donor age and donor-recipient human leukocyte antigen (HLA)-match, according to an article published online ahead of print in Blood.1
Investigators evaluated the association between donor characteristics (ie, age, sex, parity, cytomegalovirus serostatus, HLA-match, and blood group ABO match) and survival following transplantation.
Continue Reading
Logistic or Cox regression models were used to examine the associations of donor characteristics with transplantation outcomes in 2 independent datasets: 1988 through 2006 (N=6,349; training cohort), and 2007 through 2011 (N=4,690; validation cohort).
Results after adjusting for patient disease and transplantation characteristics showed a survival benefit with grafts from young donors (18 to 32 years) who were HLA-matched to recipients (P < .001).
RELATED: Hematopoietic Cell Transplant Linked With Better Survival Outcomes
There was a 5.5% increase in the haqard ratio for overall mortality with every 10-year increment in age. Differences in HLA were associated with a decrease in survival.
Sex, parity, and cytomegalovirus serostatus were not linked to survival.
Investigators concluded that the effect of ABO matching on survival is modest and merits further study.
Reference
- Kollman C, Spellman SR, Zhang M-J, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy [published online ahead of print November 2, 2015]. Blood. doi: 10.1182/blood-2015-08-663823.
